Showing results (101-110 of 209) with videos related to

Sort By:
Pageof 21
Pediatric Blood & Cancer|September 7, 2022
Imaging of pediatric extremity soft tissue tumors: A COG Diagnostic Imaging Committee/SPR Oncology Committee White PaperMichael Richard Acord, Erika Pace, Alexander El-Ali, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 14, 2024
Theranostic Intratumoral Convection-Enhanced Delivery of 124I-Omburtamab in Patients with Diffuse Intrinsic Pontine Glioma: Pharmacokinetics and Lesion DosimetryNeeta Pandit-Taskar, Pat B Zanzonico, Milan Grkovski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2021
Imaging Tumor-Infiltrating Lymphocytes in Brain Tumors with [64Cu]Cu-NOTA-anti-CD8 PETVeronica L Nagle, Kelly E Henry, Charli Ann J Hertz, et al.
Abdominal Radiology (New York)|October 29, 2022
FDG-PET/MRI for the preoperative diagnosis and staging of peritoneal carcinomatosis: a prospective multireader pilot studyNaik Vietti Violi, Somali Gavane, Pamela Argiriadi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2007
Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumorsMichael J Morris, Neeta Pandit-Taskar, Chaitanya R Divgi, et al.
Pediatric Blood & Cancer|November 9, 2022
Clinical outcomes of pediatric patients receiving multimodality treatment of second central nervous system relapse of neuroblastomaKathryn R Tringale, Suzanne L Wolden, Dana L Casey, et al.
International Journal of Radiation Oncology, Biology, Physics|May 8, 2012
Positron emission tomography (PET) evaluation after initial chemotherapy and radiation therapy predicts local control in rhabdomyosarcomaKavita V Dharmarajan, Leonard H Wexler, Somali Gavane, et al.
European Journal of Radiology|May 11, 2016
Metabolic tumor volume and total lesion glycolysis on FDG-PET/CT can predict overall survival after (90)Y radioembolization of colorectal liver metastases: A comparison with SUVmax, SUVpeak, and RECIST 1.0Waleed Shady, Sirish Kishore, Somali Gavane, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2019
Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177Lu-Satoreotide TetraxetanDiane Reidy-Lagunes, Neeta Pandit-Taskar, Joseph A O'Donoghue, et al.
EJNMMI Research|March 7, 2018
I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinomaJorge A Carrasquillo, Joseph A O'Donoghue, Volkan Beylergil, et al.
Pageof 21